Cancer Genomics Consortium
EIN: 273232063 · Fletcher, NC · NTEE: H12
Is Cancer Genomics Consortium Legit?
Insufficient Data
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
About Cancer Genomics Consortium
Cancer Genomics Consortium (EIN: 273232063) is a nonprofit organization based in Fletcher, NC, classified under NTEE code H12. The organization reported total revenue of $437K and total assets of $556K according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Cancer Genomics Consortium's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Cancer Genomics Consortium is a small nonprofit that has been operating for 12 years, with 11 years of IRS 990 filings on record (2013–2023). Revenue has grown at a compound annual rate of 8.4%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $441K |
| Total Expenses | $447K |
| Surplus / Deficit | $-5,507 |
| Total Assets | $580K |
| Total Liabilities | $74K |
| Net Assets | $507K |
| Operating Margin | -1.2% |
| Debt-to-Asset Ratio | 12.7% |
| Months of Reserves | 15.6 months |
Financial Health Grade: B
In 2023, Cancer Genomics Consortium reported a deficit of $6K with expenses exceeding revenue, holds 15.6 months of operating reserves (strong position), has a debt-to-asset ratio of 12.7% (very low leverage).
Financial Trends
Over 11 years of filings (2013–2023), Cancer Genomics Consortium's revenue has grown at a compound annual growth rate (CAGR) of 8.4%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | -6.5% | +17.4% | +8.5% |
| 2022 | +63.2% | +110.5% | +13.7% |
| 2021 | +85.9% | +24.4% | +30.0% |
| 2020 | -52.5% | -53.0% | +19.9% |
| 2019 | +13.4% | +19.3% | +6.5% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1000 |
| IRS Ruling Date | 2014 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Analysis Pending
AI enrichment for Cancer Genomics Consortium has not yet been completed. Basic IRS 990 data is shown below. Check back later for a full transparency report including a Mission Score, spending breakdown, executive compensation analysis, and red flags assessment.
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Cancer Genomics Consortium with a Mission Score of 0 out of 100 (Very Poor). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a deficit of $6K, with expenses exceeding revenue.
- Debt-to-asset ratio: 12.7%.
Frequently Asked Questions about Cancer Genomics Consortium
Is Cancer Genomics Consortium a legitimate charity?
Based on AI analysis of IRS 990 filings, Cancer Genomics Consortium (EIN: 273232063) insufficient data. 0 red flags identified, 0 strengths noted.
How does Cancer Genomics Consortium spend its money?
Detailed spending breakdown data is not yet available for Cancer Genomics Consortium. Check back for updated IRS 990 analysis.
Are donations to Cancer Genomics Consortium tax-deductible?
Cancer Genomics Consortium is registered as a tax-exempt nonprofit (EIN: 273232063). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
Filing History
IRS 990 filing history for Cancer Genomics Consortium showing financial trends over 11 years of public records:
Over 11 years of IRS 990 filings (2013–2023), Cancer Genomics Consortium's revenue has grown by 123.6%, moving from $197K to $441K. Total assets increased by 256.4% over the same period, from $163K to $580K. Total functional expenses rose by 195.9%, from $151K to $447K. In its most recent filing year (2023), Cancer Genomics Consortium reported a deficit of $6K, with expenses exceeding revenue. The organization holds $74K in liabilities against $580K in assets (debt-to-asset ratio: 12.7%), resulting in net assets of $507K.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $441K | $447K | $580K | $74K | — | — |
| 2022 | $472K | $380K | $535K | $23K | — | View 990 |
| 2021 | $289K | $181K | $470K | $50K | — | View 990 |
| 2020 | $156K | $145K | $362K | $50K | — | View 990 |
| 2019 | $327K | $309K | $302K | $0 | — | View 990 |
| 2018 | $289K | $259K | $283K | $0 | — | View 990 |
| 2017 | $207K | $194K | $253K | $0 | — | View 990 |
| 2016 | $147K | $155K | $240K | $0 | — | View 990 |
| 2015 | $170K | $88K | $248K | $0 | — | View 990 |
| 2014 | $128K | $125K | $166K | $0 | — | View 990 |
| 2013 | $197K | $151K | $163K | $0 | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $441K, expenses of $447K, and assets of $580K (revenue -6.5% year-over-year).
- 2022: Revenue of $472K, expenses of $380K, and assets of $535K (revenue +63.2% year-over-year).
- 2021: Revenue of $289K, expenses of $181K, and assets of $470K (revenue +85.9% year-over-year).
- 2020: Revenue of $156K, expenses of $145K, and assets of $362K (revenue -52.5% year-over-year).
- 2019: Revenue of $327K, expenses of $309K, and assets of $302K (revenue +13.4% year-over-year).
- 2018: Revenue of $289K, expenses of $259K, and assets of $283K (revenue +39.4% year-over-year).
- 2017: Revenue of $207K, expenses of $194K, and assets of $253K (revenue +40.8% year-over-year).
- 2016: Revenue of $147K, expenses of $155K, and assets of $240K (revenue -13.5% year-over-year).
- 2015: Revenue of $170K, expenses of $88K, and assets of $248K (revenue +33.2% year-over-year).
- 2014: Revenue of $128K, expenses of $125K, and assets of $166K (revenue -35.3% year-over-year).
- 2013: Revenue of $197K, expenses of $151K, and assets of $163K.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Cancer Genomics Consortium:
Data Sources and Methodology
This transparency report for Cancer Genomics Consortium is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.